Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. provides model-informed and AI-accelerated drug development software, training, and consulting services for biopharmaceutical research. News about the company centers on its software and services segments, scientific modeling engines, ADMET and other modeling workflows, and financial results tied to software renewals, services bookings, and customer activity.
Recurring developments also include collaborations with pharmaceutical companies, technology providers, and regulatory or public-health agencies. These updates cover GPU-accelerated simulation, AI-assisted modeling, predictive frameworks for complex oral drug products, computational toxicology, new approach methodologies, and education programs that expand use of model-informed drug development practices.
Simulations Plus, a leader in biosimulation software, will present at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 2:00 p.m. ET. CEO Shawn O’Connor will discuss the company's advancements in modeling and simulation for pharmaceutical safety and efficacy. The session will be webcast live and available for replay on the Simulations Plus website. Established for over 25 years, Simulations Plus provides innovative solutions to major pharmaceutical and regulatory agencies worldwide.
Simulations Plus has launched ILDsym™ version 1A, a quantitative systems pharmacology modeling software aimed at enhancing therapy development for Interstitial Lung Disease (ILD)/b) in systemic sclerosis patients. Sponsored by a leading biotech firm, ILDsym is designed to help inform clinical trial designs, potentially addressing the challenges presented by SSc-ILD. The software can model critical disease mechanisms and improve patient outcomes. The company is also positioned to expand ILDsym's application across various diseases due to its customizable nature.
Simulations Plus (NASDAQ: SLP) announces a collaboration with a large pharmaceutical company to enhance its ADMET Predictor® platform. The partner will provide tens of thousands of proprietary pKa measurements to improve prediction accuracy and extend chemical coverage. This initiative aims to reinforce ADMET Predictor as the leading property prediction tool in drug discovery, leveraging advanced machine learning techniques. The collaboration is expected to significantly advance predictive modeling within the pharmaceutical sector.
Simulations Plus (NASDAQ: SLP) announced the presentation of five scientific posters at the PAGE conference in Ljubljana, Slovenia, from June 28 to July 1, 2022. The conference gathered over 600 scientists focused on data analysis through a population approach. Dr. Jonathan Chauvin emphasized the importance of the event for discussing advancements in modeling and simulation, particularly the MonolixSuite platform. New developments presented include algorithms aimed at enhancing NLME modeling, contributing to the increasing adoption of MonolixSuite.
Summary not available.
Simulations Plus (NASDAQ: SLP) has launched a Concierge Program aimed at fostering strategic partnerships with pharmaceutical companies and contract research organizations. This initiative is designed to enhance customer support through regular communication and collaboration, helping clients to expedite their development programs. Notable successes have been reported, including tailored training for regulatory scientists and customized software solutions across North America, Europe, and South America. The program demonstrates SLP's commitment to understanding clients' evolving needs in the pharmaceutical landscape.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 17% total revenue growth for Q3 fiscal 2022, reaching $15.0 million. The software revenue rose by 16% to $9.7 million, while services revenue grew by 19% to $5.3 million. Diluted EPS increased by 11% to $0.20, with a net income of $4.1 million. The company reiterated its full-year revenue guidance of $52-53 million and announced a quarterly dividend of $0.06 per share, payable August 1, 2022.
Simulations Plus, Inc. (Nasdaq: SLP) reported record attendance at the 2022 Pharmacometrics Spring School, with 936 participants from over 50 countries. The event featured workshops on model-informed drug development and clinical trial simulations using the MonolixSuite and PKanalix platforms, both offered free to attendees. Dr. Jonathan Chauvin highlighted strong community interest which supports the company's position as a leader in modeling and simulation software. The company aims to continue these workshops in 2023.
Simulations Plus, Inc. (NASDAQ: SLP) revealed its Cognigen division's collaboration with a major pharmaceutical firm to enhance the development of a COVID-19 therapy. This partnership facilitated modeling and simulation activities, significantly contributing to regulatory submissions. The project focused on real-time data processing, improving insights on pharmacokinetics and efficacy throughout clinical trials. Cognigen division president Jill Fiedler-Kelly emphasized the essential role of these services in optimizing drug development efficiency.
Simulations Plus (SLP) will report its third-quarter financial results for fiscal year 2022, ending May 31, 2022, after market close on July 6, 2022. A conference call will be held at 5:00 PM ET on the same day, allowing stakeholders to engage with company representatives. Interested parties can join the call by registering here or by calling 1-201-389-0879.